Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q2 2023 call → NOThe question asks whether management conveys that outsiders are currently underweighting something the company has already done, and whether management points to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let me analyze the transcript for both elements: (1) Recognition gap management itself raises - does management indicate the company is being measured or perceived in an outdated way? (2) A concrete, already-in-place thing that backs the claim, with its payoff still ahead. Looking at the transcript: - Amnon discusses the SuperVision business, ZEEKR vehicles, the nine OEM prospects, the Volkswagen relationship, etc. - He talks about the ZEEKR rollout: "the full SuperVision capability is being delivered to ZEEKR vehicles over time to over the air updates" and "ZEEKR recently significantly broadened the number of users with Highway Navigate on Pilot and we expect a full rollout to all users within weeks." - He discusses the NOP feature being offered free for six months, then revenue kicking in 2024: "the NOP feature powered by REM is for the first six months is going to be offered for free to all the ZEEKR customers, and then we will start seeing revenue based on a certain traction, we will see revenue. And so that should kick in 2024. So we are talking about 100 of dollars per vehicle potential in 2024." This is interesting - the ZEEKR system is already operating, already in production, with 120,000 SuperVision enabled vehicles in China, more than 1000 beta testers. The NOP feature is being rolled out now, and the revenue from it is still ahead (2024). Does management raise a recognition gap? Let me look... Amnon says: "We have noted an increase in seriousness within the OEMs over the past one, two years, and have seen some OEMs that appear to be far away from us on advanced technology move rapidly to align behind our approach." He also discusses the competitive landscape and how the ZEEKR system is performing better than competitors. But is there a specific statement that outsiders are underweighting something? Let me look for that... The question about 2024 SuperVision volumes: Amnon says "our 300K unit outlook for next year assume that ZEEKR 001 would sustain its Q4 2022 demand pace in China...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.